Celltrion Healthcare reports on progress with higher predose levels of the infliximab biosimilar Remsima in patients with Crohn disease (CD) and ulcerative colitis (UC).
Patients with Crohn disease (CD) and ulcerative colitis (UC) were shown to benefit from use of subcutaneous (SC) infliximab (Remsima; CT-P13) in terms of efficacy and lower fecal calprotectin (FC) levels, according to Incheon, Republic of Korea–based Celltrion Healthcare.
FC is a protein biomarker associated with active inflammatory bowel disease, which includes UC and CD. Celltrion said the findings suggest better clinical outcomes are possible via use of higher predose levels of SC infliximab.
“These promising results support the use of the subcutaneous formulation of Remsima in inflammatory bowel disease as an alternative option for eligible patients with UC and CD,” said Walter Reinisch, director of the Clinical Inflammatory Bowel Disease Study Group for the Department of Gastroenterology and Hepatology at the Medical University of Vienna. The findings were presented at United European Gastroenterology Week Virtual 2020.
Study on FC Response
In 1 of 2 studies Celltrion presented, the infliximab biosimilar as a predose serum was evaluated according to clinical efficacy and FC response in patients with CD and UC.
Among the 54 patients enrolled in the CT-P13 SC arm who completed maintenance treatment up to week 54, 77.8% (42) achieved clinical remission.
The analysis showed that patients with the highest exposure to infliximab (>26.7 μg/mL) experienced the highest efficacy outcomes.
Study on Mucosal Monitoring
The second study was a controlled trial that investigated the accuracy of the use of FC in monitoring mucosal changes in patients with moderate to severe UC who received CT-P13 in either intravenous (IV) or SC form.
Results of the trial revealed that FC levels are associated with positive changes in mucosal inflammation, specifically with improved endoscopic activity in patients with UC who are treated with CT-P13 in SC form.
“The use of FC for monitoring the mucosal response to infliximab SC presents a viable, noninvasive choice for monitoring treatment—providing patients and clinicians with greater flexibility to suit their needs,” Reinisch said.
The multicenter, randomized, controlled pivotal trial enrolled 68 patients with UC, with 33 receiving CT-P13 in SC form and 35 receiving CT-P13 in IV form. At baseline, the median FC level was 880 mcg/g (786 mcg/g and 978 mcg/g in the SC and IV arms, respectively).
At week 22, the proportion of patients with FC levels greater than 250 mcg/g decreased to 39% (n = 23), amounting to 44.4% (n = 12) of patients in the SC arm and 34.4% (n = 11) of patients in the IV arm.
Celltrion said that, overall, 86.98% (n = 59) achieved FC levels greater than 250 mcg/g, with this occurring in 87.9% (n = 29) of patients in the SC arm and 85.7% (n = 30) in the IV arm.
In July, Remsima SC (CT-P13 SC) was granted marketing authorization from the European Commission for an additional 5 indications to include ankylosing spondylitis, CD, UC, psoriatic arthritis, and psoriasis.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.